US 11,807,634 B2
Cyclopropyl dihydroquinoline sulfonamide compounds
Benjamin C Milgram, Cambridge, MA (US); Isaac E Marx, Arlington, MA (US); John Stellwagen, Beverly, MA (US); Wei Zhao, Westford, MA (US); and Alan H. Cherney, Somerville, MA (US)
Assigned to AMGEN INC., Thousand Oaks, CA (US)
Filed by AMGEN INC., Thousand Oaks, CA (US)
Filed on Jun. 10, 2021, as Appl. No. 17/344,939.
Claims priority of provisional application 63/036,999, filed on Jun. 10, 2020.
Prior Publication US 2021/0387977 A1, Dec. 16, 2021
Int. Cl. C07D 413/12 (2006.01)
CPC C07D 413/12 (2013.01) 27 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
an enantiomer, diastereoisomer, atropisomer thereof, a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
R1 is a cyclopropyl ring; or a 4-, 5-, 6-, 7-, or 8-membered bicyclic ring containing 0, 1, 2 or 3 N atoms and 0, 1, or 2 atoms selected from O and S; and wherein said cyclopropyl ring or bicyclic ring is substituted by 0, 1, 2 or 3 R1a groups selected from hydroxy, halo, C1-8alk, C1-8haloalk, —O—C1-4alk, —O—C1-8haloalk, —C(═O)C1-4alk, —O—C(═O)C1-4alk, —NH2,
—NHC1-4alk, —N(C1-4alk)C1-4alk, 3-, 4-, or 5-membered cycloalkyl, or 6-membered aryl;
R2 is H, halo, CN, C1-6alk, or C1-6haloalk;
R3 is C1-6alk, C1-6haloalk, —O—C1-6alk, —O-cyclopropyl, or —O-cyclobutyl;
R4 is a 5- to 6-membered heteroaryl;
Each of R6 and R7 is hydrogen; and
Each of R5a; R5b; R5c; R5d; and R5e is independently hydrogen or halo,
wherein the compound is not

OG Complex Work Unit Chemistry
or a salt or tautomer thereof.